A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002106
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
- Detailed Description
Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Pacific Oaks Med Group
🇺🇸Sherman Oaks, California, United States
Duke Univ Med Ctr
🇺🇸Durham, North Carolina, United States
Houston Clinical Research Network
🇺🇸Houston, Texas, United States
Community Research Initiative
🇺🇸Coral Gables, Florida, United States